Zeffix 100 mg Film-coated tablet
Authorisation EU/1/99/114/002 · GlaxoSmithKline Trading Services Limited
- Licence holder
- GlaxoSmithKline Trading Services Limited (all products →)
- Active substance
- Lamivudine
- Clinical trials
- 7 clinical trials →
- Dosage form
- Film-coated tablet
- Route of administration
- Oral use
- ATC codes
- J05AF, J05AF05
- First authorised
- 29/07/1999
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
Lamivudine: supply and approvals
20 authorised products on the HPRA list contain Lamivudine. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 20 Nov 2026)
- US shortage (FDA)
-
Lamivudine Injection: resolved, updated 16 Nov 2026
Lamivudine Tablet: resolved, updated 19 Oct 2026 - Germany (BfArM)
- No entry in the BfArM supply notices (checked 20 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 114. It has been authorised for 27 years (since 29 July 1999). The HPRA list does not say whether it is on sale.
Other medicines with Lamivudine in Ireland
19 other products on the HPRA list contain Lamivudine, from 6 licence holders; 1 of them is marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Abacavir/Lamivudine Viatris 600 mg/300 mg Film-coated Tablets | Viatris Limited | National authorisation (PA) | Marketed |
| Abacavir/Lamivudine Mylan 600 mg/300 mg film-coated tablets | McDermott Laboratories Ltd., T/A Gerard Laboratories | National authorisation (PA) | Not marketed |
| Combivir 150 mg/300 mg film-coated tablets | ViiV Healthcare BV | Centralised EU authorisation | Not stated |
| Combivir 150 mg/300 mg film-coated tablets | ViiV Healthcare BV | Centralised EU authorisation | Not stated |
| Delstrigo 100 mg/300 mg/245 mg film-coated tablets | Merck Sharp & Dohme BV, | Centralised EU authorisation | Not stated |
| Dovato 50 mg/300 mg tablets | ViiV Healthcare BV | Centralised EU authorisation | Not stated |
| Epivir 10 mg/ml oral solution | ViiV Healthcare BV | Centralised EU authorisation | Not stated |
| Epivir 150 mg film-coated tablets | ViiV Healthcare BV | Centralised EU authorisation | Not stated |
| Epivir 300 mg film-coated tablets | ViiV Healthcare BV | Centralised EU authorisation | Not stated |
| KIVEXA | ViiV Healthcare BV | Centralised EU authorisation | Not stated |
| Lamivudine Teva 100 mg film-coated tablets | Teva Pharma B.V. | Centralised EU authorisation | Not stated |
| Lamivudine Teva Pharma B.V. 150 mg film-coated tablets | Teva Pharma B.V. | Centralised EU authorisation | Not stated |
Other substances in ATC group J05AF
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 9 other active substances share the group J05AF with this product:
Entecavir (5) · Tenofovir disoproxil fumarate (5) · Zidovudine (3) · Emtricitabine (1) · ENTECAVIR MONOHYDRATE (1) · Tenofovir disoproxil (1) · Tenofovir disoproxil phosphate (1) · Tenofovir alafenamide (1) · Abacavir sulfate (1)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
GlaxoSmithKline Trading Services Limited holds 28 products on the HPRA list, with 14 different active substances; 0 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.